DEFA14A: Recursion Pharmaceuticals to Acquire Exscientia in $688 Million AI-Driven Drug Discovery Deal

Recursion Pharmaceuticals is set to acquire Exscientia in an all-stock deal valued at $688 million, aiming to create an end-to-end, tech-enabled drug discovery platform.

Summary

• Recursion Pharmaceuticals announced a proposed acquisition of Exscientia in an all-stock deal valued at $688 million.
• The acquisition aims to combine Recursion's automated platform and massive data sets with Exscientia's precision chemistry capabilities.
• The goal is to create a full-stack, tech-enabled drug discovery solution to bring better medicines to patients faster and at a lower cost.
• Recursion currently has five programs in human clinical trials and expects to read out seven clinical trials in the next 18 months.
• With the acquisition of Exscientia, the combined company hopes to read out 10 clinical trials in the next 18 months.
• Recursion believes its competitive advantage lies in its proprietary data, consisting of over 50 petabytes from real experiments.
• The company emphasizes that the ultimate goal is to deliver medicines to patients, regardless of whether they are developed using AI or traditional methods.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the acquisition and its potential benefits for drug discovery. While acknowledging the risks and challenges, the overall tone is optimistic about the future of the combined company.

Positives

• The acquisition of Exscientia is expected to create a more comprehensive drug discovery platform.
• The combined company anticipates faster and more efficient drug development processes.
• Recursion's existing clinical trial programs are progressing, with multiple readouts expected soon.
• The company's focus on data and AI is seen as a competitive advantage in the drug discovery space.
• The acquisition aims to bring better medicines to patients sooner and at a lower cost.

Negatives

• The success of the acquisition depends on the ability to successfully integrate Exscientia's business with Recursion's.
• The company acknowledges that drug discovery is a long and expensive process, typically taking 12 to 15 years and costing billions of dollars.
• The company is still in the early stages of proving the effectiveness of its AI-driven approach.
• The deal is subject to stockholder and shareholder approval, regulatory approvals, and sanction of the High Court of Justice of England and Wales.

Risks

• The transaction agreement could be terminated due to unforeseen events or changes.
• The inability to obtain necessary approvals could prevent the completion of the acquisition.
• The integration of Exscientia's business may be disruptive and could divert management's attention.
• The combined company may face challenges in retaining key personnel.
• The expected benefits of the acquisition, including cost synergies, may not be realized.
• Legal proceedings could arise following the announcement of the proposed combination.
• Economic, market, or business conditions could negatively impact the combined company's operations.
• Changes in interest rates, inflation, and supply chain disruptions could pose challenges.
• The company faces risks related to conducting business internationally.
• The market value of Recursion's common stock to be issued in the proposed combination could be impacted.

Future Outlook

The combined company aims to accelerate drug discovery, reduce costs, and bring better medicines to patients faster. Recursion anticipates multiple clinical trial readouts in the next 18 months and hopes to increase that number with the acquisition of Exscientia.

Management Comments

• Chris Gibson, CEO of Recursion, stated that the acquisition will create an end-to-end, full-stack solution of tech-enabled drug discovery.
• Gibson emphasized the importance of data as a competitive moat in the AI-driven drug discovery space.
• Gibson highlighted the goal of bringing better medicines to patients sooner and at a lower cost.

Industry Context

The announcement reflects the growing trend of using AI and machine learning in drug discovery to improve efficiency and reduce costs. The combination of Recursion and Exscientia aims to create a more competitive player in the biopharma industry.

Comparison to Industry Standards

• The traditional drug discovery process typically takes 12-15 years and costs billions of dollars, according to industry averages.
• Recursion aims to significantly reduce this timeline and cost through its AI-driven platform.
• Other companies in the AI-driven drug discovery space include Schrodinger, Relay Therapeutics, and Atomwise, each employing different approaches to leverage AI for drug development.
• The success of Recursion's approach will be measured against the industry standard of clinical trial success rates and time-to-market for new drugs.

Stakeholder Impact

• Shareholders may benefit from the potential value creation of the combined company.
• Employees may experience changes due to the integration of the two businesses.
• Patients may benefit from faster and more efficient drug discovery processes.
• Business partners may see changes in their relationships with the company.
• The acquisition could impact competition in the biopharma industry.

Next Steps

• Obtain Recursion's stockholder approval and Exscientia's shareholder approval.
• Receive regulatory approvals for the proposed combination.
• Obtain the sanction of the High Court of Justice of England and Wales to the Scheme of Arrangement.
• Successfully integrate Exscientia's business with Recursion's business.
• Read out results from ongoing clinical trials.

Key Dates

Keywords

drug discovery, artificial intelligence, AI, acquisition, Exscientia, Recursion Pharmaceuticals, clinical trials, data, biotech, pharmaceuticals